Pictor’s Playbook: Scaling Diagnostics by Solving Science and Economics

CARLSBAD, CA – June 02, 2026 – In the bustling biotech hub of Carlsbad, California, a company that began its journey in New Zealand is marking its first year with a series of quiet but significant victories. Pictor Holdings Inc. isn't just celebrating an anniversary; it's methodically executing a strategy to rewire a fundamental part of laboratory science. The company’s mission is to solve a persistent problem in healthcare and research: the trade-off between speed, cost, and complexity in detecting disease. While many labs rely on legacy tests that look for one marker at a time, the future lies in seeing the bigger picture. Pictor believes it has found the way to deliver that future, not just to elite research institutions, but to mainstream labs across the globe.

In its first twelve months stateside, the company has secured four strategic partnerships, launched seven products, and raised $5 million in a pre-Series A round. Now, with a seasoned leadership team and its sights set on a $30 million Series A, Pictor is betting that its blend of accessible technology and a shrewd business model is the key to unlocking the next era of diagnostics.

The Science and the Economics

At the heart of Pictor's strategy is its targeted proteomic platform. Proteomics, the large-scale study of proteins, offers a dynamic snapshot of health and disease. While discovery-based proteomics can profile thousands of proteins, it is often prohibitively expensive and slow for routine use. Pictor focuses on targeted proteomics, analyzing a curated set of up to 20 key protein biomarkers in a single sample. This approach delivers clinically relevant insights without the noise and cost of a full-scale discovery workflow.

The platform's specifications are designed to dismantle existing barriers. It can process a 96-well plate in under two hours, delivering results at a cost below market rates. This efficiency is powered by the company's AI-enabled PictImager® imaging system and its customizable Pictorial© software, which automates analysis and integrates with existing lab systems. Crucially, the platform is built upon proven, reliable diagnostic technology, making it easier for labs to adopt.

"The companies that define the next era of laboratory science will be the ones that solve both the science and the economics simultaneously," said Tim Shannon, Pictor's new Chief Financial Officer. "Pictor's platform does that — and the commercial model means that as adoption scales, the business scales with it. That's a compelling foundation to build on."

This business model is a critical piece of the puzzle. Instead of building a massive internal sales force, Pictor pursues a partner-led strategy. It provides the technology and manufactures the assays, while its partners—pharmaceutical companies, large reference labs, and animal health firms—own the customer relationships. Pictor earns recurring revenue for every test run, creating a scalable, capital-efficient path to growth. This model is designed to align interests and accelerate market penetration, a key differentiator in a competitive landscape.

Building Momentum Through Strategic Partnerships

For any platform technology, early validation is paramount. Pictor’s first year in the U.S. has been defined by securing the kind of commercial traction that signals genuine market demand. The company has formalized four strategic partnerships, including a confidential collaboration with a top-20 global pharmaceutical company—a significant endorsement of its technology's potential.

Another key partnership is with Disease Research Limited (DRL) in New Zealand. This collaboration focuses on launching the PictVet® MAP assay for monitoring Johne's disease, a chronic wasting illness in cattle. The partnership, which builds on a multi-year scientific relationship and a peer-reviewed study, demonstrates a clear real-world application in the multi-billion dollar animal health market. By providing a more efficient multi-analyte test, Pictor helps farmers and veterinarians manage herd health more effectively and economically.

Beyond these anchor deals, the company reports a pipeline of five additional active agreements spanning oncology, wellness, and the consolidation of older ELISA tests. This diverse interest underscores the platform’s flexibility.

"A year ago, we joined the innovative Carlsbad biotech community. We believe the market is eager for accessible targeted proteomic workflows," noted CEO and Co-founder Dr. Jamie Platt. "What the past twelve months have shown us is that the demand is real, the partnerships are real, and the platform performs. Our second year is about scale — more partners, more markets, and more of the science that makes this platform genuinely differentiated."

Fueling the Next Phase of Growth

With proven demand, Pictor is now focused on securing the capital to meet it. The recently closed $5 million pre-Series A convertible note, supported by both long-term shareholders and a new U.S. investor, serves as a bridge to a much larger ambition: a Series A funding round of up to $30 million.

The proceeds are earmarked for a strategic expansion across the entire business. Pictor plans to scale its assay development and manufacturing capabilities to support its growing list of partners. It will also expand its team, bolster its intellectual property portfolio, which already includes 16 granted patents, and fund large-scale translational studies. These studies are crucial for generating the data needed to move from research-use to licensed diagnostic products, a key inflection point for value creation over the next 12 to 18 months.

A Leadership Team Built for Scale

Executing such an ambitious plan requires a leadership team with a specific blend of scientific vision and commercial acumen. Pictor has strategically assembled a roster that appears tailor-made for the task. CEO Jamie Platt has over two decades of experience in diagnostics, having guided multiple products to market and played a key role in M&A deals totaling nearly $1 billion.

Significantly, the recent hires of COO Dr. Terry Kelly and CFO Tim Shannon round out the executive suite with directly relevant expertise. Kelly brings over 20 years of experience in assay development and a clear focus on operational excellence. "Building workflows, systems, and partner relationships that can enable labs to expand their current capabilities and make the science accessible at scale. That's the work I'm here to do," he stated.

Meanwhile, the appointment of Shannon reunites him with Platt, with whom he co-led the strategic partnership and subsequent acquisition of Inivata. This history suggests a proven dynamic for navigating the path from innovation to a successful financial exit. With a team that understands both the lab bench and the balance sheet, Pictor is positioning itself not just as a scientific innovator, but as a disciplined, high-growth business poised to make a lasting impact on the diagnostics industry.